MRK Stock Surges 14% With A 7-day Winning Spree On Analyst Upgrades, Earnings Beat
Merck (MRK) – a developer of human and animal pharmaceutical products and vaccines – hit a 7-day winning streak, with cumulative gains over this period amounting to 14%. The company’s market cap has surged by about $37 Bil over the last 7 days and currently stands at $304 Bil.
The stock has YTD (year-to-date) return of 15.8% compared to 1.3% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Rally?
[1] Multiple Analyst Price Target Hikes
- Guggenheim PT To $140, Wells Fargo To $135
- TD Cowen PT Raised To $120
- Impact: Increased Investor Confidence, Positive Price Momentum
[2] Q4 2025 Earnings And Revenue Beat
- Q4 Revenue Of $16.4B Exceeds Estimates
- Q4 EPS Of $2.04 Beats Consensus
- Impact: Stock Price Jump, Validates Growth Story
[3] Technical Breakout Confirmation
- Broke Above Prior 2023 And 2025 Resistance
- SIA SMAX Score Of 8 Out Of 10
- Impact: Breached Key Resistance Levels, Attracted Momentum Traders
Opportunity or Trap?
Below is our take on valuation.
There are only a couple of things to fear in MRK stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell MRK).
But here is the real interesting point.
You are reading about this 14% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that have not surged yet.
Returns vs S&P 500
The following table summarizes the return for MRK stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | MRK | S&P 500 |
|---|---|---|
| 1D | 1.8% | 2.0% |
| 7D (Current Streak) | 14.1% | -0.7% |
| 1M (21D) | 12.3% | 0.2% |
| 3M (63D) | 45.7% | 2.0% |
| YTD 2026 | 15.8% | 1.3% |
| 2025 | 9.8% | 16.4% |
| 2024 | -6.3% | 23.3% |
| 2023 | 1.0% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 88 S&P constituents with 3 days or more of consecutive gains and 18 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 34 | 3 |
| 4D | 19 | 8 |
| 5D | 13 | 5 |
| 6D | 7 | 2 |
| 7D or more | 15 | 0 |
| Total >=3 D | 88 | 18 |
Key Financials for Merck (MRK)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $60.1 Bil | $64.2 Bil |
| Operating Income | $3.0 Bil | $20.2 Bil |
| Net Income | $365.0 Mil | $17.1 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $15.8 Bil | $17.3 Bil |
| Operating Income | $5.6 Bil | $6.6 Bil |
| Net Income | $4.4 Bil | $5.8 Bil |
While MRK stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.